ZIG
ALGS icon

Zullo Investment Group’s Aligos Therapeutics ALGS Stock Holding History

Zullo Investment Group’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-520
Closed -$4.55K – 151
2024
Q2 		$4.55K Hold
520
– – ﹤0.01% 151
2024
Q1 		$12.7K Hold
520
– – 0.01% 154
2023
Q4 		$8.63K Buy
+520
New +$8.94K ﹤0.01% 149

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Zullo Investment Group's ALGS Position: Q3 2024 in Review

Zullo Investment Group sold out of Aligos Therapeutics (ALGS) in Q3 2024, closing a stake of 520 shares — an estimated $4.55K sold.

Zullo Investment Group first reported a position in ALGS in Q4 2023 and held it in 3 quarters. The position peaked at $12.7K in Q1 2024. 27 funds tracked by Wall St. Rank hold ALGS as of Q3 2024.

  • Zullo Investment Group reported no remaining Aligos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Zullo Investment Group sold 520 Aligos Therapeutics shares in Q3 2024, an estimated $4.55K.
  • Zullo Investment Group first reported a position in Aligos Therapeutics in Q4 2023 and held it in 3 quarters.
  • Zullo Investment Group's Aligos Therapeutics position peaked at $12.7K in Q1 2024.
  • 27 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2024.

Based on Zullo Investment Group's 13F filing for Q3 2024, filed 15 Oct 2024.